β-Secretase (BACE1) is the rate-limiting protease for the generation of the amyloid β-peptide (Aβ) in Alzheimer disease. Mice in which the bace1 gene is inactivated are reported to be healthy. However, the presence of a homologous gene encoding BACE2 raises the possibility of compensatory mechanisms. Therefore, we have generated bace1, bace2, and double knockout mice. We report here that BACE1 mice display a complex phenotype. A variable but significant number of BACE1 offspring died in the first weeks after birth. The surviving mice remained smaller than their littermate controls and presented a hyperactive behavior. Electrophysiologically, subtle alterations in the steady-state inactivation of voltage-gated sodium channels in BACE1-deficient neurons were observed. In contrast, bace2 knockout mice displayed an overall healthy phenotype. However, a combined deficiency of BACE2 and BACE1 enhanced the bace1+/− lethality phenotype. At the biochemical level, we have confirmed that BACE1 deficiency results in an almost complete block of Aβ generation in neurons, but not in glia. As glia are 10 times more abundant in brain compared with neurons, our data indicate that BACE2 could indeed contribute to Aβ generation in the brains of Alzheimer disease and, in particular, Down syndrome patients. In conclusion, our data challenge the general idea of BACE1 as a safe drug target and call for some caution when claiming that no major side effects should be expected from blocking BACE1 activity.

Alzheimer disease (AD) is the most common cause of dementia for which neither a good diagnostic test nor an effective treatment is available yet. The most widely accepted hypothesis states that AD is initially triggered by the abnormal accumulation and possibly deposition of the small amyloid β-peptide (Aβ) in different brain regions, which in turn initiates a pathogenic cascade that ultimately leads to neuronal death, AD pathology, and dementia. Aβ is cleaved from a long membrane-bound precursor, the amyloid precursor protein (APP), by two consecutive cleavages. β- and γ-secretases are the enzymes that liberate the N and C termini of Aβ, respectively, and are the subject of intense investigation because of their relevance as candidate therapeutic targets to treat AD.

BACE1 and BACE2 are two highly homologous membrane-bound aspartyl proteases that can process APP at the β-secretase site (1–8). Although both enzymes exhibit many of the characteristics expected for β-secretase, it has been quite convincingly demonstrated that BACE1 is in fact the major β-secretase responsible for Aβ generation in brain (9–11). Contrary to BACE1, BACE2 is more highly expressed in peripheral tissues, but also to some extent in brain (2, 8, 12, 13), raising the question of whether BACE2 could contribute to the generation of the brain Aβ pool. Both BACE1 and BACE2 can cleave APP in vitro not only at Asp1 (numbering considering the first amino acid of Aβ as position 1), but also at internal sites within the Aβ region. BACE1 cleaves between amino acids 10 and 11 of Aβ, resulting in a N-terminally truncated peptide that is considered more amyloidogenic and more neurotoxic than full-length Aβ (14) and that has been observed in senile plaques (15, 16). The internal BACE2 cleavage site is between amino acids 19 and 20 (8, 17, 18), and the resulting Aβ has thus far not been found in senile plaques. Moreover, BACE2-transfected cells produce reduced levels of Aβ (2, 8, 13, 18), and selective knockdown of endogenous BACE2 in human embryonic kidney 293 cells by RNA interference elevates Aβ secretion (19). These observations led to the suggestion that BACE2 does not function as a β-secretase, but rather as an α-like secretase that precludes Aβ formation (17–20). However, these in vitro observations cannot rule out a possible contribution of BACE2 to the

The abbreviations used are: AD, Alzheimer disease; Aβ, amyloid β-peptide; APP, amyloid precursor protein; SFV, Semliki Forest virus; APPwt, wild-type APP; APPsw, Swedish APP mutation; APPfl, Flemish APP mutation; MEM, minimal essential medium; VSV, vesicular stomatitis virus.
Aβ pool in brain, and it has even been suggested that BACE2-mediated APP cleavage might play a role in the development of AD in individuals carrying the Flemish familial AD mutation in APP (8) as well as in the AD-like disease associated with Down syndrome (12, 21).

From a therapeutic point of view, there are increasing concerns with using γ-secretase inhibitors to treat AD. γ-Secretase processes a growing number of membrane proteins, and blocking their cleavage is likely to have toxic side effects. Indeed, administration of a potent γ-secretase inhibitor to mice results in marked defects in lymphocyte development and in intestinal villi and mucosa (22), as was also observed in presenilin-deficient mice (23). In contrast, BACE1 appears to be a promising drug target because genetic ablation of the bace1 gene in mice does not seem to be associated with any gross abnormality (9–11). Moreover, BACE1 deficiency could prevent the learning and memory impairments and the cholinergic dysfunction observed in a transgenic mouse model for AD (24). Although BACE1 function might still be required under particular conditions that may have escaped detection, these results highlight BACE1 as one of the best available drug targets for AD. At this point, however, it cannot be excluded that BACE1 has important functions in vivo and that the apparent lack of phenotype in bace1 knockout mice is due to the activation of compensatory mechanisms or to genetic redundancy. Because of their high homology, BACE2 is the best candidate protease to compensate for the absence of BACE1 function. Based on this homology, it is also likely that active-site inhibitors for BACE1 will affect, in addition, BACE2 protease activity.

To better understand the biological functions of BACE1 and BACE2, to analyze possible overlapping functions of these two proteases, and to attempt to predict the consequences of blocking BACE function in vivo, we generated mice with inactivated bace1 and/or bace2 genes. Unexpectedly and in contrast to what has been published for bace1 knockout mice, we observed a phenotype associated with BACE1 deficiency, viz. a higher mortality rate early in life. bace2 knockout mice were fertile and viable, with no major phenotypic alteration. Most important, mice with inactivated bace1 and bace2 genes were fertile and viable, but presented neonatal mortality that was even higher than that of the monogenic bace1 line. These results suggest that BACE2 indeed partially compensates for the absence of BACE1 in bace1 knockout mice and that therapeutic inhibition of BACE function may result in adverse side effects.

**EXPERIMENTAL PROCEDURES**

**Antibodies**—The C terminus-specific antibody for mouse BACE1 (B48) was raised in New Zealand White rabbits using synthetic peptide CLRHQHDDFADDISLLK. Rabbit antibodies B7/8 raised against Aβ (B48) was raised in New Zealand White rabbits using synthetic peptide CLRHQHDDFADDISLLK. Rabbit antibodies B63 raised against the C terminus of human APP (26) have been described. Anti-FLAG monoclonal antibody was from Sigma. The N terminus-specific antibody for human Aβ (82E1) was from IBL Co., Ltd. (Tokyo, Japan).

**Plasmid Construction**—cDNAs to be expressed in non-neuronal cells were subcloned into a derivative of the eukaryotic expression vector pSECl (Stratagene) that contains a larger polylinker (pS75**: polylinker EcoRI, Spel, SacI, HindIII, NotI, XhoI, Smal, SacI, BamHI, and BglII). BACE1 cDNA was amplified from mouse brain RNA using primers 5'-GGATTCTAGCCCCAGCGTCAGTCTGGCT-3' and 5'-GAGCTCTCTAGAGGAGGAAATGATC-3' (with the SacI site underlined) and directly cloned into pGEM-T (Promega). The SacI-SphI fragment was subsequently subcloned into the Sac-SphI sites of pS75**. BACE2 cDNA was amplified from mouse pancreas cDNA using primers 5'-ATGGGCGCCGCTGTCTGCGAGCAC-3' and 5'-TCATTTCCAGCGATGTTCGAC-3' and cloned into the pGEM-T vector. The XmnI fragment of pGEM-T-mBACE2 was subsequently subcloned into the Smal site of pS75**. For cloning of BACE2 cDNA containing a deletion of exon 6 (BACE2ΔE6), two subfragments of the cDNA were separately amplified using primers that contain the deletion. The 5'-fragment was amplified using T7 as the forward primer and 5'-AGAAAATCTCGGAAATCCTTCGAGGTGTAGGCTCATG-3' as the reverse primer. The 3'-fragment was amplified using primers 5'-CTGGACTCCAGAGAGATCCCTGCACTGGTCA-3' and 5'-GCTGCAATAAACAAGTTCTGCT-3'. The purified 5'– and 3'-subfragments were mixed together and PCR-amplified using the T7 and 5'-GCTGCAATAAACAAGTTCTGCT-3' primers. The PCR product was digested with EcoRI and BamHI and cloned into the same sites of pS75**. Cloning of bace2 and bace2ΔE6 containing a C-terminal FLAG epitope was done by PCR amplification on pSG10** BACE2 and pS75**. BACE2ΔE6, respectively, using primers 5'-GGATTCTAGCCCCAGCGTCAGTCTGGCT-3' and 5'-GAGCTCTCTAGAGGAGGAAATGATC-3' (with the SacI site underlined) and 5'-GGATCTCAGTTATAGCTGGTGATCTTCTTTCCCGATGTCGTAGT-3' (with the BamHI site underlined and the FLAG epitope in itals). PCR products were digested with EcoRI-BamHI and cloned into the same sites of the pS75** vector. All constructs were verified by sequencing.

For expression in neuronal and glial cells, cDNAs were cloned into Semiliki Forest virus (SFV) type 1. Cloning of SFV-APPwt, SFV-APPsw, and SFV-APPfl has been described previously (27, 28).

**Primary Cultures and Cell Lines**—Medium, serum, and supplements for maintenance of cells were obtained from Invitrogen. COS cells and adult mice fibroblasts were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum. Primary neuronal cultures were generated from trypsinized brains obtained from day 14 embryos and maintained in Neurobasal medium (Invitrogen) supplemented with B27 and 0.5 μM t-glutamine. Cytosine arabinoside (5 μM) was added 24 h after plating to prevent non-neuronal (glial) cell proliferation. For glial cell cultures, Neurobasal medium was replaced with minimal essential medium (MEM; Invitrogen) supplemented with 5% horse serum, 0.225% NaHCO3, 2 mM t-glutamine, and 0.6% glucose (MEM-HS). Cultures were maintained at 37 °C in a humidified 5% CO2 atmosphere.

**DNA Transfer and Metabolic Labeling**—COS cells were plated in 6-cm2 plates 1 day before transfection. Approximately 70–80% confluent cells were transfected with a total of 2 μg of DNA (1 μg of APP and 1 μg of BACE plasmids) and 6 μl of FuGene 6 (Roche Applied Science). Cells were further transfected the following day with 100 μCi/ml [35S]methionine for 4 h; the conditioned medium was collected; and cells were directly lysed in double immunoprecipitation assay buffer (50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS).

Neurons were maintained in Neurobasal medium, and ~48 h after the addition of cytosine arabinoside, they were infected with recombinant SFV. Glial cells were harvested 1–2 weeks in MEM-HS, passaged at least once, and infected with recombinant SFV ~48 h after trypanosporisation. (This treatment ensured the absence of neurons in the culture.) For both neurons and glial cells, a 10-fold dilution of SFV encoding APPwt, APPsw, or APPfl was added to the cultures, and infection was allowed to proceed for 1 h. The conditioned medium containing the virus was replaced with fresh serum-free medium and SFV-APPfl has been described previously (27, 28).

**Analysis of APP Processing**—Full-length APP and C-terminal fragments were immunoprecipitated from cell extracts using antibody B63. Aβ was immunoprecipitated from the conditioned medium using anti-body B7/8. Protein G-Sepharose beads (Amersham Biosciences) were added to the mixtures, followed by overnight incubation at 4 °C with rotation. The immunoprecipitates were washed five times with Tris-buffered saline containing protease inhibitors (Trasylol, 1 μg/ml; leupeptin, 1 μg/ml). The immunoprecipitates were then resuspended in radiolabeled bands were detected on 4–12% precast gels (Novex). Radiolabeled bands were detected on 4–12% precast gels (Novex). Radiolabeled bands were detected on 4–12% precast gels (Novex). Radiolabeled bands were detected on 4–12% precast gels (Novex).
medium using antibody 2B7/8 and detected by Western blotting using antibody 82E1.

**Fluorescence Resonance Energy Transfer Analysis**—COS cells were transfected with 2 μg of either empty vector or vector encoding BACE1-FLAG, BACE2-FLAG, or BACE2α6-FLAG using 6 μl of FuGene 6. Forty-eight hours after transfection, cells were scraped in buffer containing 5 mm Tris (pH 7.4), 250 mM sucrose, 1 mM EGTA, and 1% Triton X-100, and protein concentration was determined using Bio-Rad protein assay dye reagent. Proteins (~400 μg) were subsequently incubated overnight at 4 °C with antibody B49 (BACE1-transfected cells) or anti-FLAG antibody (BACE2-transfected cells) and protein G-Sepharose beads. The immunoprecipitates were washed three times with Tris-buffered saline containing 0.1% Triton X-100 and twice with Tris-buffered saline. BACE activity was subsequently measured in an *in vitro* assay (Panvera P2985) by fluorescence resonance energy transfer according to the manufacturer’s instructions. Briefly, an APP-based peptide substrate was incubated for 45 min at 29 °C in HEPES-buffered saline (150 mM NaCl, 3 mM CaCl2, 2 mM MgCl2, 1.25 mM NaHPO4, 25 mM NaHCO3, and 10 mM β-glucose (pH 7.4). Small pieces of slices tissue (~2 × 2 mm) were fixed for 45 min at 29 °C in HEPES-buffered saline (150 mM NaCl, 3 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, and 10 mM β-glucose (pH 7.4)) containing 19 units/ml papain. All recordings were made at room temperature (19–20 °C). Current signals from acutely isolated pyramidal cell somata recorded in whole cell voltage clamp mode were sampled at 20 kHz and filtered at 5 kHz (~3 dB) using an Axopatch 200B amplifier in conjunction with a Digidata 1322A interface and pClamp 9 software (all from Axon Instruments, Inc., Foster City, CA). Access resistance in the whole cell configuration was 10–15 MΩ, and 10 MΩ of series resistance compensation (75–80%). To improve voltage control, Na+ currents were investigated in a low Na+ bathing solution containing 15 mM NaCl, 115 mM choline chloride, 3 mM KCl, 2 mM MgCl2, 1.6 mM CaCl2, 0.4 mM CdCl2, 10 mM HEPES, and 10 mM β-glucose (pH 7.4). Small Y-shaped pipettes were filled with 105 mM CsF, 20 mM triethanolamine chloride, 3 mM KCl, 1 mM MgCl2, 8 mM HEPES, 9 mM EGTA, and 2 mM Na-ATP (pH 7.2 adjusted with CsODA). Data are presented as means ± S.E. Data were statistically analyzed (Student’s *t* test, significance set at *p* < 0.05) using Origin Pro7 software. Substances were purchased from Sigma.

**Animals**—A panel of 69 male mice (25 wild-type, 23 heterozygous, and 21 *bace1* knockout littermate mice, aged 3–9 months) was used to assess anxiety-related behavior in the open field test and elevated zero maze and depression-related behavior in the tail suspension test and forced swim test. Animals were individually housed and kept under a 12:12 light:dark cycle (lights on at 6:00 a.m.) in a temperature- and humidity-controlled room with food and water *ad libitum*. All experiments were conducted during the light phase of the light/dark cycle with 1 week between experiments.

**Open Field Test**—Locomotor activity was monitored using a Truscan® system (Coulbourn Instruments Inc., Allentown, PA). The animal was placed in the center of the activity field arena, which is a transparent plexiglas cage (260 width × 260 depth × 400 height mm) equipped with two photo beam sensor rings to register horizontal and vertical movements. Testing lasted 30 min.

**Elevated Zero Maze**—Elevated zero maze testing was performed as described by Crawley (30). The zero maze consists of an annular platform (diameter, 50 cm; and width, 5 cm). The animals were allowed to freely explore the maze for 5 min, and their behavior was recorded and analyzed using the Ethovision Pro video tracking system (Noldus Information Technology, Wageningen, The Netherlands).

**Tail Suspension Test**—Mice were suspended by their tail in a test chamber using adhesive tape. Total duration of immobility was measured over a period of 6 min using the VideoTrack system (Viewpoint, Champagne au Mont D’Or, France). Mice that curled up toward their tail or fell out of during testing were excluded from analysis.

**Forced Swim Test**—A mouse was placed in a cylinder (inner diameter, 10 cm) filled with water to a height of 10 cm at a temperature of 24 ± 1 °C. The mouse was exposed to swim stress for 6 min. Total duration of immobility was measured using the VideoTrack system. One animal was excluded from analysis because it had a very high fat mass and had difficulties staying afloat.

**Statistical Analysis**—Data were analyzed by one-way analysis of variance or by Kruskal-Wallis analysis of variance on ranks in case data were not normally distributed, followed by post hoc Tukey’s test (one-way analysis of variance) or Dunn’s method (Kruskal-Wallis analysis of variance on ranks) if appropriate.

**RESULTS**

**Lethal Phenotype in bace1 Knockout Mice**—Several groups have reported the generation of *bace1* knockout mice (9–11). We generated an independent line of BACE1-deficient mice (line BACE1; supplemental “Experimental Procedures”). Briefly, a neomycin expression cassette was inserted within the first coding exon of the *bace1* gene at codon 49, resulting in the introduction of a premature in-frame translational stop codon. The absence of BACE1 protein was confirmed by Western blotting of extracts from embryonic brains using a C terminus-specific antibody against BACE1 (Fig. 1A). BACE1-deficient mice appeared at first glance viable and fertile. However, during expansion of the colony in two different conventional facilities in Leuven and in Kiel, we observed increased lethality among BACE1-deficient pups in the first weeks after birth. Mortality was almost exclusively restricted to the *bace1*−/− group (Fig. 1B). Of 180 *bace1* knockout pups born to *bace1* knockout parents, 34 (19%) died within the first 3–6 days of birth. Of those remaining, 44 (~24%) showed growth retardation (see, for example, Fig. 1D) and died by 3–4 weeks of age from a wasting syndrome. In contrast, mortality in the wild-type and heterozygous groups did not exceed 2% (Fig. 1B). The high neonatal death observed in *bace1*−/− pups was not caused by a nursing defect of BACE1-deficient mothers. In a pup exchange experiment, there was no reduction in neonatal mortality of *bace1* knockout pups born to *bace1* knockout parents when they were nursed by a wild-type mother (Fig. 1C). Finally, healthy *bace1* null mice were ~30% smaller by weight than control mice. This was observed in BACE1 heterozygous crosses (weight measured by 3 weeks of age, 8.3 ± 0.9 g for wild-type mice, 9.1 ± 0.4 g for *bace1*−/− mice, and 5.8 ± 0.4 g for *bace1*−/− mice) (data not shown) and further confirmed in BACE1 and BACE2 heterozygous crosses (Fig. 1E). The BACE1-deficient mice surviving to adulthood were fertile, and histological and anatomical examination failed to evidence any gross phenotypic abnormality (supplemental Fig. 4) (data not shown).

To exclude the possibility that mortality in our colony was due to a defect independent of BACE1 deficiency, a second BACE1-deficient line was independently generated (line BACE1II; supplemental “Experimental Procedures”). A similar mortality rate was observed with those mice (data not shown), demonstrating that mortality is directly linked to BACE1 deficiency.

**BACE1** is known to cleave both PSGL-1 (P-selectin glycoprotein ligand-1) and β-galactoside α2,6-sialyltransferase I, proteins implicated in immune reactions (31–33), and therefore, we performed a series of *in vitro* and *in vivo* assays to evaluate the ability of BACE1-deficient animals to mount an efficient immune response. We first tested whether *bace1*−/− mice could mount an efficient immune response to vesicular stomatitis virus (VSV) infection. To this end, *bace1*−/− mice and heterozygous and wild-type littermates were intravenously challenged with 2 × 10⁶ plaque-forming units of VSV. On day 4 after
infection, all mice analyzed mounted similar VSV-neutralizing IgM responses that switched to the IgG isotype by day 8 and reached plateau levels at later time points (supplemental Fig. 5). Thus, adaptive immunity was functional in bace1−/− mice, i.e. VSV-neutralizing T help-independent IgM and the T help-dependent switch to the IgG subtype were normally induced. Furthermore, a similar resistance to lethal VSV infection at higher infection doses (data not shown) suggested that the overall quality and quantity of VSV-specific immunity were very similar for all genotypes. We further checked (a) the number and type of leukocytes that migrated into the peritoneum in a model of acute peritonitis induced by thioglycollate (34, 35), (b) the activation of macrophages in vitro as evaluated by tumor necrosis factor-α secretion upon stimulation with pathogens (Mycobacterium avium and Mycobacterium tuberculosis) or with lipopolysaccharide, and (c) the T-cell responses as measured by the capacity of activated T-cells isolated from spleens of preimmunized mice to destroy chromium-labeled cells from a different genetic background. All these experiments were negative (data not shown), suggesting that the overall immune defense of the bace1 knockout animals is not dramatically compromised.

**Behavioral Analysis of BACE1-deficient Mice**—We tested bace1 knockout mice (strain BACE1II) in a battery of behavioral tests (Fig. 2). In the open field test, bace1 null mice displayed hyperactivity and enhanced locomotion compared with heterozygous and wild-type littersmates, as illustrated by a significant increase in total move time (F(2,66) = 10.743, p < 0.001) (Fig. 2A) and total distance traveled (H = 16.387, p < 0.05) (Fig. 2B). The bace1 genotype had, however, no effect on the relative time spent in the center and the relative distance traveled in the center (data not shown). This indicates that bace1 knockout mice do not show an anxiolytic or anxiogenic phenotype, which was confirmed in the elevated zero maze test.

![BACE1 and BACE2-deficient Mice](image-url)
In this test, BACE1-deficient mice showed a significant increase in the total distance traveled ($F(2,65) = 21.926$, $p < 0.001$) (Fig. 2C), again pointing to a hyperactive phenotype. One mouse with a homozygous genotype actively jumped off the maze and was excluded from the analysis. Furthermore, there was a significant effect of genotype on the relative time spent in the open arms ($F(2,65) = 4.003$, $p = 0.023$) (Fig. 2D). Post hoc analysis revealed that bace1 null mice exhibited an increase in the relative time spent in the open arms compared with heterozygous littermates ($p = 0.05$). This stresses no indication of anxiety. No influence of genotype on the relative distance traveled in the open arms could be detected (data not shown). Finally, animals were tested in the tail suspension and forced swim tests, which are both validated models for assessing depression-related behaviors. As shown in Fig. 2E, there was no significant effect of genotype on immobility in the tail suspension test ($F(2,59) = 1.085$, $p = 0.345$). In the forced swim test, homozygous animals showed a significant decrease in immobility time compared with heterozygous and wild-type animals ($F(2,65) = 16.625$, $p < 0.001$) (Fig. 2F). This difference probably reflects a hyperactive rather than an antidepressant phenotype. Results are presented as means ± S.E. * $p < 0.05$ versus wild-type mice.

In this test, BACE1-deficient mice showed a significant increase in the total distance traveled ($F(2,65) = 21.926$, $p < 0.001$) (Fig. 2C), again pointing to a hyperactive phenotype. One mouse with a homozygous genotype actively jumped off the maze and was excluded from the analysis. Furthermore, there was a significant effect of genotype on the relative time spent in the open arms ($F(2,65) = 4.003$, $p = 0.023$) (Fig. 2D). Post hoc analysis revealed that bace1 null mice exhibited an increase in the relative time spent in the open arms compared with heterozygous littermates ($p < 0.05$). This stresses no indication of anxiety. No influence of genotype on the relative distance traveled in the open arms could be detected (data not shown). Finally, animals were tested in the tail suspension and forced swim tests, which are both validated models for assessing depression-related behaviors. As shown in Fig. 2E, there was no significant effect of genotype on immobility in the tail suspension test ($F(2,59) = 1.085$, $p = 0.345$). In the forced swim test, homozygous animals showed a significant decrease in immobility time compared with heterozygous and wild-type animals ($F(2,65) = 16.625$, $p < 0.001$) (Fig. 2F). This difference probably reflects a hyperactive rather than an antidepressant phenotype. Results are presented as means ± S.E. * $p < 0.05$ versus wild-type mice.

Na$^+$ Currents in Cortical Neurons of bace1 Knockout Mice—BACE1 has been recently shown to cleave $\beta$- and $\gamma$-subunits of voltage-gated Na$^+$ channels in mouse brain (36). These $\beta$-subunits are auxiliary subunits that associate with the principal pore-forming $\alpha$-subunit and that regulate the function and expression of voltage-gated Na$^+$ channels (37). We hence wondered whether the genetic ablation of bace1 would influence the properties of the fast Na$^+$ current. To address this issue, we performed whole cell recordings from pyramidal cell somata that were acutely isolated from slices of mouse neocortex. We chose this preparation because BACE1 is highly expressed in neurons of this brain region (36) and because dissociated cells offer the advantage of allowing adequate spatiotemporal voltage control of fast Na$^+$ currents. After pharmacological suppression of voltage-dependent Ca$^{2+}$ and K$^+$ currents with Cd$^{2+}$ and Cs$^{+}$/triethanolamine, respectively (see “Experimental Procedures”), fast Na$^+$ currents were gradually activated by step depolarizations to command potentials between −60 and 10 mV (Fig. 3A). To determine the current-voltage relationship of the Na$^+$ current, the peak current amplitude at each voltage step was normalized to the neuron’s capacitance and plotted as a function of the command potential (Fig. 3B). Cortical neurons from bace1 knockout mice had a tendency to display lower Na$^+$ current densities than those from wild-type mice, but this difference did not reach statistical significance. The activation curve of the Na$^+$ conductance ($G$) was constructed from the current-voltage relationship of Fig. 3B using the equation $G = I(V - E_{Na})$, where $I$ is the peak current amplitude at command potential $V$ and $E_{Na}$ is the
equilibrium potential for Na$^+$ under our experimental conditions. As shown in Fig. 3C (open symbols), the activation curve of the Na$^+$ conductance did not differ between neurons from wild-type and bace1$^{-/-}$ mice. Steady-state inactivation of Na$^+$ currents was determined by holding the neuron for 1 s at prepulse potentials between −100 and −20 mV before evoking a Na$^+$ current response with a voltage step to 0 mV. Current amplitudes were expressed as a fraction of the maximal current amplitude and plotted as a function of the prepulse potential. In contrast to activation, steady-state inactivation did vary significantly between neurons from wild-type and BACE1-deficient mice (Fig. 3C, closed symbols). The rightward shift of the steady-state inactivation curve in neurons from BACE1-deficient mice (wild-type mice, $V_h = 65$ mV (dashed curve); and
BACE1- and BACE2-deficient Mice

BACE1 knockout mice, $V_h = -58$ mV (solid curve) indicates that a larger fraction of Na$^+$ channels is available at a given potential compared with neurons from wild-type mice. Recovery from inactivation was studied by gradually increasing the interval (1 ms to 2 s) between two 15-ms test pulses to 0 mV. The peak amplitude of the second Na$^+$ current response divided by the response at the maximal interval was then plotted as a function of the interpulse interval. As shown in Fig. 3D, recovery from inactivation was not significantly different between the two groups.

Generation and Characterization of bace2 Knockout Mice—To understand the in vivo function of the β-secretase homolog BACE2, a bace2 knockout mouse line was generated. Two loxP sites were first introduced in the introns flanking exon 6, which contains one of the two active sites of the enzyme. Mice heterozygous for the bace2 conditional targeted allele were subsequently crossed with mice expressing Cre recombinase from the ubiquitous phosphoglycerate kinase promoter, resulting in the deletion of bace2 exon 6 (BACE2ΔE6) (supplemental “Experimental Procedures”). To demonstrate that the BACE2ΔE6 protein does not have β-secretase activity, BACE1, BACE2, and BACE2ΔE6 expressed in COS cells were immunoprecipitated from cell extracts, and protease activity was measured in an in vitro assay using a synthetic peptide representing the BACE1 cleavage site of APPsw. Only BACE1 and BACE2 (but not BACE2ΔE6) were capable of cleaving the peptide (Fig. 4). Western blotting confirmed that similar levels of BACE2 and BACE2ΔE6 were tested in the assay (Fig. 4). Thus, the BACE2ΔE6 protein encoded in bace2 knockout mice lacks protease activity.

Mice homozygous for the deficient bace2 allele were born at normal frequency and were fertile and healthy overall. No difference in size could be identified when compared with littermate controls (Fig. 1, D and E). In a standard battery of blood and clinical chemistry parameters, no abnormality associated with the genotype was detected (data not shown). Extensive pathological analysis of four bace2+/− and four bace2−/− mice with hematoxylin and eosin staining failed to show any abnormality related to genotype (supplemental “Experimental Procedures”).

Generation and Characterization of bace1−/−bace2−/− Knockout Mice—To identify putative major BACE functions that could be compensated for in the single monogenic bace knockout lines, we generated mice deficient in both BACE1 and BACE2 proteases. Interestingly, double knockout mice had a neonatal mortality of ~60%, which was higher than that observed in the single BACE1-deficient line (Fig. 1B). Of 122 double knockout mice born to double knockout parents, 51 (~42%) died within the first 3–5 post-natal days. An additional 24 pups (~20%) died within the first 3–4 weeks from a wasting syndrome. The surviving animals were fertile, and a detailed pathological examination failed to reveal any abnormality (supplemental “Experimental Procedures”) (data not shown). Like bace1 knockout mice, healthy double knockout animals remained smaller than their control littermates (Fig. 1, D and E).

Processing of APP in BACE-deficient Cells—We next analyzed the processing of APP in cells derived from knockout animals. We started with primary neurons because, although BACE1 is expressed at relatively high levels in neurons, BACE2 expression in these cells is still a matter of debate (2, 13, 19). We analyzed in parallel APPwt, APPsw, and APPfl. APPsw and APPfl were chosen because both mutations are represented as means ± S.E. DKO, double knockout; ko, knockout. Mouse fibroblasts were derived from the peritonea and diaphragma of adult mice and immortalized by stable expression of the SV40 large T antigen (C). Fibroblasts were transduced with recombinant adenovirus expressing APPsw. Processing of APP was analyzed as described under “Experimental Procedures.” All experiments were performed at least three times. However, we observed a novel APP C-terminal fragment that migrated slightly faster than the β1 C-terminal fragment (Fig. 5A, asterisk). BACE2 is not responsible for this cleavage be-
cause the same fragment was still produced in double BACE1/BACE2-deficient neurons. The facts that bace1 knockout neurons did not produce any measurable Aβ and that there was no measurable effect on APP processing in primary neurons deficient in BACE2 confirm that BACE1 is the only β-secretase in these cells. Glial cells are the most abundant cells in brain, and we next investigated how APP processing is affected by the absence of BACE proteases. Interestingly, BACE1-deficient glial cells secreted measurable levels of Aβ, which were more prominent in APPsw- and APPfl-transduced cells (Fig. 5B). Moreover, although wild-type cells overexpressing APPsw produced about four times higher levels of Aβ compared with APPfl-overexpressing cells, the situation changed in BACE1-deficient cells. In this case, similar amounts of Aβ were generated by the APPsw and APPfl mutants, and the amounts generated by these mutants were slightly higher than those produced by APPwt-expressing glial cells. This is consistent with BACE2 being the responsible protease because it has been shown that the Flemish mutation in APP markedly increases Aβ production by BACE2 (8). That BACE2 contributes to Aβ generation in cultured glial cells is also demonstrated by the fact that, in BACE1-deficient glial cells, we observed significant Aβ generation, which was reduced to undetectable levels only in the combined BACE1/BACE2 deficiency. These data suggest that BACE2 is expressed in glial cells and might contribute to Aβ production in vivo in these cells.

To demonstrate that the Aβ measured in these experiments was generated by cleavage at the authentic β-secretase site, we made use of antibody 82E1, which specifically recognizes the neoeptope produced upon BACE cleavage of APP at Asp1 (38). Similar to the results described above, BACE1-deficient glial cells (but not neurons) continued to generate Aβ detected by antibody 82E1 (Fig. 6), demonstrating that the observed cleavage was carried out by a β-secretase.

Finally, we analyzed processing of APPsw in fibroblasts derived from BACE-deficient mice (Fig. 5C). Analogous to neuronal cells, there was a compensatory cleavage of APP in bace1 knockout fibroblasts that resulted in the generation of a C-terminal fragment similar to that observed in neurons. Double knockout cells still produced this fragment, demonstrating that, as in neurons, BACE2 is not responsible for this compensatory cleavage. Interestingly, fibroblasts deficient in the BACE2 enzyme secreted higher levels of Aβ compared with wild-type cells. These results indicate that fibroblast endogenous BACE2 has an anti-amyloidogenic function in vivo.

**DISCUSSION**

We generated mouse lines that are deficient in BACE1, BACE2, or both. Previous reports claimed that genetic ablation of bace1 does not result in overt phenotypic alterations (9–11, 39). One group reported a more timid, more anxious, and less exploratory behavior in these mice (40). In contrast, we found a complex but significant phenotype in our two independently generated bace1 knockout strains, which are characterized by increased neonatal mortality affecting up to ~40% of newborn animals. The surviving mice were healthy and fertile, but displayed a lower weight. They showed also hyperactivity and enhanced locomotion in a battery of behavioral tests. The phenotype of BACE2-deficient mice has not been reported previously. We found thus far no indications of any physiological or anatomical abnormalities when the animals were kept under similar breeding conditions as our BACE1 strains. This is somewhat surprising because BACE2 is ubiquitously expressed in fetal and adult tissues (12), and further work is needed to determine more precisely the physiological role of BACE2. The increased neonatal mortality observed in bace1/bace2 double knockout mice compared with single BACE1 deficiency indicates, however, that at least some overlap exists between BACE1 and BACE2 functions. It is unclear at the moment why one group of bace1 and double knockout mice died within the first weeks after birth, whereas others survived into adulthood. Possible explanations for this diversity include effects of modifier genes and varying levels of compensatory contributions from other (related) genes. Mortality seems to be associated with an environmentally born factor that triggers death only in combination with BACE1 deficiency. This probably explains why other groups did not observe mortality in their bace1−/− strains and is supported by the fact that the BACE1III line presented neonatal mortality only when the animals were housed in the same facility as the BACE1 line, but not in the specific pathogen-free facility where they originally came from (data not shown). Because BACE1 is known to cleave both PSGL-1 and β-galactoside α2,6-sialyltransferase 1, proteins implicated in immune reactions (31–33), we speculated that the higher mortality rate observed in bace1 knockout mice might reflect a deficient immune response in a non-pathogen-free environment. The analyses we performed thus far (see “Results”) failed, however, to reveal any defect of bace1 knockout mice in their capacity to mount an efficient immune response. We excluded also the possibility that bace1 knockout mothers are deficient in milk production or do not care for their pups by performing pup exchange experiments (Fig. 1C). Because the lethality rate did not decrease when the knockout pups were nursed by wild-type mothers and because no lethality was observed when BACE1-deficient mothers nursed wild-type pups, we conclude that the lethality problem is linked with BACE1 deficiency in the pups. Because the adult mice displayed an abnormal hyperactive behavior (Fig. 2), it remains an interesting speculation that behavioral alterations in the pups could contribute to lethality. There are, however, no behavioral tests available for newborn mice to evaluate this possibility in further detail.

It was recently shown that BACE1 cleaves the β-subunits of voltage-gated sodium channels (36). The β-subunits belong to the immunoglobulin superfamily of cell adhesion molecules,
and besides their cell adhesion function, they play a role in channel gating and cell-surface expression of the pore-forming α-subunits (41). Given the prominent expression of BACE1 in the striatum (36), it is tempting to speculate that changes in Na+ channel function might contribute to the hyperactive phenotype of bace1 null mice reported in this study. We checked this by performing whole cell recordings from cortical neurons. We found that the lack of BACE1 was associated with a significant shift in steady-state inactivation of the Na+ current toward more depolarized potentials. In contrast, the voltage dependence of activation was not altered. The shift in steady-state inactivation might be functionally important because it increases the availability of Na+ channels in the critical voltage range around the firing threshold. In addition to modulating Na+ currents, BACE might also regulate synaptic function. Kamenetz et al. (42) recently proposed a feedback loop in which Aβ plays a prominent role. According to their model, an increase in neuronal activity induces BACE1, leading to enhanced production of Aβ, which in turn depresses excitatory synaptic transmission. Thus, blockade of BACE1 might be expected to influence neuronal excitability at both the cellular and neuronal network levels, and such alterations might manifest as the subtle behavioral deficits observed in BACE1-deficient mice. Again, further work is needed to firmly establish cause-consequence relationships in this regard.

We finally analyzed in detail the role of BACE1 and BACE2 in APP processing. We have confirmed that BACE1 is the major β-secretase in vivo and is basically the only β-secretase that is active in neurons. Interestingly, cultured glial cells derived from bace1 knockout mice still secreted in the conditioned medium measurable amounts of an Aβ-like peptide. This peptide was no longer detected in double BACE1/BACE2 null mice reported in this study. We checked for kindly providing antibody 82E1, Dr. Wim Annaert (Katholieke Universiteit Leuven) and Dr. Collin Dingwall (GlaxoSmithKline) for contributing anti-Aβ antibodies, Dr. Norbert Reil for helping analyze macrophage function, and Marlies Rusch for technical assistance.
